• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

(18)F-FACBC(抗1-氨基-3-(18)F-氟环丁烷-1-羧酸)与(11)C-胆碱PET/CT在前列腺癌复发中的比较:一项前瞻性试验的结果

(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.

作者信息

Nanni Cristina, Zanoni Lucia, Pultrone Cristian, Schiavina Riccardo, Brunocilla Eugenio, Lodi Filippo, Malizia Claudio, Ferrari Matteo, Rigatti Patrizio, Fonti Cristina, Martorana Giuseppe, Fanti Stefano

机构信息

Nuclear Medicine, AOU Policlinico S.Orsola-Malpighi, Via Massarenti, 9 40138, Bologna, Italy.

Urology, AOU Policlinico S.Orsola-Malpighi, Bologna, Italy.

出版信息

Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10. doi: 10.1007/s00259-016-3329-1. Epub 2016 Mar 10.

DOI:10.1007/s00259-016-3329-1
PMID:26960562
Abstract

PURPOSE

To compare the accuracy of (18)F-FACBC and (11)C-choline PET/CT in patients radically treated for prostate cancer presenting with biochemical relapse.

METHODS

This prospective study enrolled 100 consecutive patients radically treated for prostate cancer and presenting with rising PSA. Of these 100 patients, 89 were included in the analysis. All had biochemical relapse after radical prostatectomy (at least 3 months previously), had (11)C-choline and (18)F-FACBC PET/CT performed within 1 week and were off hormonal therapy at the time of the scans. The two tracers were compared directly in terms of overall positivity/negativity on both a per-patient basis and a per-site basis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were calculated for both the tracers; follow-up at 1 year (including correlative imaging, PSA trend and pathology when available) was considered as the standard of reference.

RESULTS

In 51 patients the results were negative and in 25 patients positive with both the tracers, in eight patients the results were positive with (18)F-FACBC but negative with (11)C-choline, and in five patients the results were positive with (11)C-choline but negative with (18)F-FACBC. Overall in 49 patients the results were false-negative (FN), in two true-negative, in 24 true-positive (TP) and in none false-positive (FP) with both tracers. In terms of discordances between the tracers: (1) in one patient, the result was FN with (11)C-choline but FP with (18)F-FACBC (lymph node), (2) in seven, FN with (11)C-choline but TP with (18)F-FACBC (lymph node in five, bone in one, local relapse in one), (3) in one, FP with (11)C-choline (lymph node) but TP with (18)F-FACBC (local relapse), (4) in two, FP with (11)C-choline (lymph nodes in one, local relapse in one) but FN with (18)F-FACBC, and (5) in three, TP with (11)C-choline (lymph nodes in two, bone in one) but FN with (18)F-FACBC. With (11)C-choline and (18)F-FACBC, sensitivities were 32 % and 37 %, specificities 40 % and 67 %, accuracies 32 % and 38 %, PPVs 90 % and 97 %, and NPVs 3 % and 4 %, respectively. Categorizing patients by PSA level (<1 ng/ml 28 patients, 1 - <2 ng/ml 28 patients, 2 - <3 ng/ml 11 patients, ≥3 ng/ml 22 patients), the number (percent) of patients with TP findings were generally higher with (18)F-FACBC than with (11)C-choline: six patients (21 %) and four patients (14 %), eight patients (29 %) and eight patients (29 %), five patients (45 %) and four patients (36 %), and 13 patients (59 %) and 11 patients (50 %), respectively.

CONCLUSION

(18)F-FACBC can be considered an alternative tracer superior to (11)C-choline in the setting of patients with biochemical relapse after radical prostatectomy.

摘要

目的

比较¹⁸F-FACBC和¹¹C-胆碱PET/CT在接受前列腺癌根治性治疗后出现生化复发患者中的准确性。

方法

本前瞻性研究纳入了100例连续接受前列腺癌根治性治疗且PSA升高的患者。在这100例患者中,89例纳入分析。所有患者均在前列腺癌根治术后(至少3个月前)出现生化复发,在1周内接受了¹¹C-胆碱和¹⁸F-FACBC PET/CT检查,且在扫描时未接受激素治疗。对两种示踪剂在每位患者和每个部位的总体阳性/阴性情况进行直接比较。计算两种示踪剂的敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)和准确性;将1年的随访(包括相关影像学检查、PSA趋势以及如有可用的病理检查)视为参考标准。

结果

51例患者两种示踪剂检查结果均为阴性,25例患者两种示踪剂检查结果均为阳性,8例患者¹⁸F-FACBC检查结果为阳性而¹¹C-胆碱检查结果为阴性,5例患者¹¹C-胆碱检查结果为阳性而¹⁸F-FACBC检查结果为阴性。总体而言,49例患者检查结果为假阴性(FN),2例为真阴性,24例为真阳性(TP),两种示踪剂检查均无假阳性(FP)。就示踪剂之间的不一致情况而言:(1)1例患者,¹¹C-胆碱检查结果为FN但¹⁸F-FACBC检查结果为FP(淋巴结),(2)7例患者,¹¹C-胆碱检查结果为FN但¹⁸F-FACBC检查结果为TP(5例为淋巴结,1例为骨,1例为局部复发),(3)1例患者,¹¹C-胆碱检查结果为FP(淋巴结)但¹⁸F-FACBC检查结果为TP(局部复发),(4)2例患者,¹¹C-胆碱检查结果为FP(1例为淋巴结,1例为局部复发)但¹⁸F-FACBC检查结果为FN,(5)3例患者,¹¹C-胆碱检查结果为TP(2例为淋巴结,1例为骨)但¹⁸F-FACBC检查结果为FN。¹¹C-胆碱和¹⁸F-FACBC的敏感性分别为32%和37%,特异性分别为40%和67%,准确性分别为32%和38%,PPV分别为90%和97%,NPV分别为3%和4%。根据PSA水平对患者进行分类(<1 ng/ml共28例患者,1 - <2 ng/ml共28例患者,2 - <3 ng/ml共11例患者,≥3 ng/ml共22例患者),¹⁸F-FACBC检查结果为TP的患者数量(百分比)总体上高于¹¹C-胆碱:分别为6例患者(21%)和4例患者(14%),8例患者(29%)和8例患者(29%),5例患者(45%)和4例患者(36%),以及13例患者(59%)和11例患者(50%)。

结论

在前列腺癌根治术后生化复发的患者中,¹⁸F-FACBC可被视为优于¹¹C-胆碱的一种替代示踪剂。

相似文献

1
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.(18)F-FACBC(抗1-氨基-3-(18)F-氟环丁烷-1-羧酸)与(11)C-胆碱PET/CT在前列腺癌复发中的比较:一项前瞻性试验的结果
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10. doi: 10.1007/s00259-016-3329-1. Epub 2016 Mar 10.
2
18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.18F-FACBC 与 11C-胆碱 PET/CT 比较在根治性前列腺切除术后生化复发患者中的前瞻性研究:28 例患者。
Clin Genitourin Cancer. 2014 Apr;12(2):106-10. doi: 10.1016/j.clgc.2013.08.002. Epub 2013 Oct 14.
3
18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.18F-氟丁醇 PET/CT 检测前列腺癌复发:与 11C-胆碱 PET/CT 的比较。
Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849.
4
Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.18F-FACBC 和 11C-胆碱 PET/CT 在根治性治疗后生化复发的前列腺癌患者中的比较:初步结果。
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S11-7. doi: 10.1007/s00259-013-2373-3. Epub 2013 Apr 17.
5
Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.使用抗3-[(18)F]FACBC PET/CT检测复发性前列腺癌:与CT的比较。
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18.
6
First case of 18F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative 11C-choline PET/CT: new imaging techniques may expand pioneering approaches.首例18F-FACBC PET/CT引导下挽救性腹膜后淋巴结清扫术用于前列腺癌根治术后疾病复发且11C-胆碱PET/CT结果为阴性的情况:新的成像技术可能会拓展开拓性方法。
Urol Int. 2014;92(2):242-5. doi: 10.1159/000354730. Epub 2013 Dec 7.
7
Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.(18)F-氟胆碱正电子发射断层扫描/计算机断层扫描(PET/CT)在前列腺癌根治术后生化复发中的临床应用:一项多中心研究结果
BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.
8
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?¹¹C-胆碱 PET/CT 在手术治疗后 PSA 轻度升高(<1.5ng/ml)的前列腺癌患者中早期发现转移疾病是否有作用?
Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):55-63. doi: 10.1007/s00259-010-1604-0. Epub 2010 Sep 17.
9
[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.18F 氟甲基胆碱(FCH)正电子发射断层扫描/计算机断层扫描(PET/CT)用于前列腺癌淋巴结分期:210 例患者的前瞻性研究。
BJU Int. 2012 Dec;110(11):1666-71. doi: 10.1111/j.1464-410X.2012.11150.x. Epub 2012 Apr 23.
10
Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?胆碱正电子发射断层扫描/计算机断层扫描(Choline PET/CT)是否会改变生化复发的前列腺癌患者的治疗管理?
Am J Clin Oncol. 2017 Jun;40(3):256-259. doi: 10.1097/COC.0000000000000139.

引用本文的文献

1
Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure.用于识别前列腺癌初次治疗失败后复发部位的正电子发射断层显像放射性示踪剂
Cancers (Basel). 2025 May 21;17(10):1723. doi: 10.3390/cancers17101723.
2
Diagnostic Capability and Improved Clinical Management of 18F-DCFPyL-PSMA PET/CT in Occult Biochemical Recurrence of Prostate Cancer After Prostatectomy.18F-DCFPyL-PSMA PET/CT在前列腺癌根治术后隐匿性生化复发中的诊断能力及改善的临床管理
Cancers (Basel). 2025 Apr 9;17(8):1272. doi: 10.3390/cancers17081272.
3
Controversies in the use of next-generation imaging for evaluation and treatment decision-making in patients with prostate cancer after biochemical recurrence: views from a Spanish expert panel.

本文引用的文献

1
18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.18F-氟丁醇 PET/CT 检测前列腺癌复发:与 11C-胆碱 PET/CT 的比较。
Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849.
2
Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.抗1-氨基-3-¹⁸F-氟环丁烷-1-羧酸:生理摄取模式、偶然发现以及可能模拟疾病的变异情况。
J Nucl Med. 2014 Dec;55(12):1986-92. doi: 10.2967/jnumed.114.143628. Epub 2014 Nov 13.
3
18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.
前列腺癌生化复发后使用新一代成像技术进行评估和治疗决策的争议:西班牙专家小组的观点
Clin Transl Oncol. 2025 Jan 2. doi: 10.1007/s12094-024-03833-6.
4
Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.前列腺癌中的雄激素信号传导:当朋友变成敌人时。
Endocr Metab Immune Disord Drug Targets. 2025;25(1):37-56. doi: 10.2174/0118715303313528240523101940.
5
An F-MD-PSMA (Multi-dentate PMSA Imaging Agent) PET/CT in Prostate Cancer Relapse: Results of a Retrospective Trial.F-MD-PSMA(多齿 PMSA 成像剂)在前列腺癌复发中的 PET/CT:一项回顾性试验的结果。
Curr Radiopharm. 2024;17(4):382-397. doi: 10.2174/1874471016666230915103157.
6
Application of next-generation imaging in biochemically recurrent prostate cancer.下一代影像学在生化复发前列腺癌中的应用。
Prostate Cancer Prostatic Dis. 2024 Jun;27(2):202-211. doi: 10.1038/s41391-023-00711-0. Epub 2023 Sep 7.
7
Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review.PSMA PET/CT时代前列腺癌根治术后复发性前列腺癌患者盆腔淋巴结照射的必要性:一项叙述性综述
Biomedicines. 2022 Dec 24;11(1):38. doi: 10.3390/biomedicines11010038.
8
The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.美国食品药品监督管理局(FDA)批准的正电子发射断层扫描(PET)成像剂在前列腺癌检测中的性能
Biomedicines. 2022 Oct 10;10(10):2533. doi: 10.3390/biomedicines10102533.
9
Management of Biochemical Recurrence of Prostate Cancer After Curative Treatment: A Focus on Older Patients.根治性治疗后前列腺癌生化复发的管理:关注老年患者。
Drugs Aging. 2022 Sep;39(9):685-694. doi: 10.1007/s40266-022-00973-8. Epub 2022 Aug 26.
10
Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer.前列腺特异性膜抗原(PSMA)PET检查在前列腺癌患者中的临床应用
Cancers (Basel). 2022 Aug 2;14(15):3768. doi: 10.3390/cancers14153768.
18F-FACBC 与 11C-胆碱 PET/CT 比较在根治性前列腺切除术后生化复发患者中的前瞻性研究:28 例患者。
Clin Genitourin Cancer. 2014 Apr;12(2):106-10. doi: 10.1016/j.clgc.2013.08.002. Epub 2013 Oct 14.
4
Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.18F-FACBC 和 11C-胆碱 PET/CT 在根治性治疗后生化复发的前列腺癌患者中的比较:初步结果。
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S11-7. doi: 10.1007/s00259-013-2373-3. Epub 2013 Apr 17.
5
Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.原发性前列腺癌患者中[18F]氟柳氯胺(氨基酸转运探针)的区域分布和动力学。
Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):394-402. doi: 10.1007/s00259-012-2291-9. Epub 2012 Dec 4.
6
Imaging techniques for local recurrence of prostate cancer: for whom, why and how?前列腺癌局部复发的影像学技术:为谁、为何以及如何应用?
Diagn Interv Imaging. 2012 Apr;93(4):279-90. doi: 10.1016/j.diii.2012.01.012. Epub 2012 Mar 30.
7
Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells.反式-1-氨基-3-氟-[1-(14)C]环丁烷羧酸在前列腺癌细胞中的转运机制。
Nucl Med Biol. 2012 Jan;39(1):109-19. doi: 10.1016/j.nucmedbio.2011.06.008. Epub 2011 Sep 29.
8
Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.应用抗 1-氨基-3-18F-氟环丁烷-1-羧酸 PET/CT 和 111In-标记的 capromab pendetide SPECT/CT 检测复发性前列腺癌。
Radiology. 2011 Jun;259(3):852-61. doi: 10.1148/radiol.11102023. Epub 2011 Apr 14.
9
Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?根治性前列腺切除术后手术切缘阳性:它们对生化或临床进展有影响吗?
BJU Int. 2008 Nov;102(10):1413-8. doi: 10.1111/j.1464-410X.2008.07791.x. Epub 2008 Jun 4.
10
A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.一种预测前列腺癌患者在初始确定性局部治疗后出现生化复发时影像学检查呈阳性概率的模型。
J Urol. 2008 Mar;179(3):906-10; discussion 910. doi: 10.1016/j.juro.2007.10.059. Epub 2008 Jan 22.